Articles related to Spark Therapeutics

Improved Sightlines
Improved Sightlines

In mid-December, the U.S. Food & Drug Administration announced approval of Luxturna (voretigene neparvovec-rzyl), the first directly administered gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene ... in this case, a rare form of inherited vision loss.

Read More
список богатых людей мира
Powered by

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: